SV Biotech Crossover Opportunities Fund LP is a venture capital fund based in London, United Kingdom. According to its most recent Form D, filed Jan 18, 2022, it has sold $135,180,000 of interests to 7 investors since its first sale in Dec 2021. The filing does not set a minimum investment. It relies on the Section 3(c)(7) exclusion, so investors generally must be qualified purchasers. The offering uses Rule 506(b), which does not permit general solicitation. Related persons named in the filing include SV Bco I GP LLP; SV Health Managers LLP; Nicola Trbovic.
- Total raised
- $135,180,000Cumulative sales reported on Form D
- Investors
- 7
- First sale
- Dec 31, 2021
- Minimum investment
- None set
- Who can invest
- Qualified purchasersSection 3(c)(7): generally $5M+ in investments
- Offering exemption
- Rule 506(b)No general advertising
- Key people and entities
- SV Bco I GP LLP; SV Health Managers LLP; Nicola Trbovic
- Latest Form D
- Jan 18, 2022
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Returns are not part of SEC filings. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction
Questions about SV Biotech Crossover Opportunities Fund LP
What is the minimum investment for SV Biotech Crossover Opportunities Fund LP?
SV Biotech Crossover Opportunities Fund LP's latest Form D, filed Jan 18, 2022, does not set a minimum investment. Managers can still require one in the offering documents.
Who can invest in SV Biotech Crossover Opportunities Fund LP?
SV Biotech Crossover Opportunities Fund LP is generally open only to qualified purchasers (generally individuals with at least $5 million in investments), because it relies on Section 3(c)(7). It uses Rule 506(b), which does not allow general advertising.
How much has SV Biotech Crossover Opportunities Fund LP raised?
SV Biotech Crossover Opportunities Fund LP reports $135,180,000 sold from 7 investors on its Form D filed Jan 18, 2022. This is cumulative sales since the offering began, not current assets or performance.
Where is SV Biotech Crossover Opportunities Fund LP based?
SV Biotech Crossover Opportunities Fund LP is based in London, United Kingdom.
When did SV Biotech Crossover Opportunities Fund LP launch?
SV Biotech Crossover Opportunities Fund LP reports its first sale in Dec 2021.
Size compared with every venture capital fund
Raised more than 93% of the 43 venture capital funds based in United Kingdom, and more than 98% of all 14,864 that report sales.